JINGHUA PHARM: Ritonavir has received approval for the listing application of chemical raw materials
I'm PortAI, I can summarize articles.
JINGHUA PHARM announced that its subsidiary Nantong Company has obtained approval from the National Medical Products Administration for the marketing application of Ritonavir chemical raw materials. This antiviral drug is primarily used for the treatment of AIDS and has also been widely used during the COVID-19 pandemic. This approval means that the raw materials meet national review standards and can be produced and sold in the domestic market in the future, enhancing the company's competitiveness in the field of chemical raw materials
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments